Nuzenio

Agomab Therapeutics Nv

Agomab Therapeutics Nv news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 7 latest news signals 5 publisher sources 100/100 entity strength

Latest news

AgomAb Therapeutics NV Stock 12‑Month Price Target Cut to $33.16, Implies 146% Upside - TradingViewTradingView · Fri, 07 Aug 2026 17:20:04 GMTAgomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanksTipRanks · Thu, 06 Aug 2026 21:41:59 GMTAgomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:13:53 GMTAgomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029 - Stock TitanStock Titan · Thu, 06 Aug 2026 20:07:36 GMTAgomab reports €252M cash and expects runway into H1 2029 - Stock TitanStock Titan · Thu, 06 Aug 2026 20:01:00 GMT36,236,779 Common shares of AgomAb Therapeutics NV are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.commarketscreener.com · Wed, 05 Aug 2026 00:22:50 GMTPrice to sales forward of AgomAb Therapeutics NV – NASDAQ:AGMB - TradingViewTradingView · Wed, 29 Jul 2026 07:36:49 GMT

Timeline

Fri, 07 Aug 2026 17:20:04 GMTAgomAb Therapeutics NV Stock 12‑Month Price Target Cut to $33.16, Implies 146% Upside - TradingView
Thu, 06 Aug 2026 21:41:59 GMTAgomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanks
Thu, 06 Aug 2026 20:13:53 GMTAgomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook - The Manila Times
Thu, 06 Aug 2026 20:07:36 GMTAgomab Therapeutics (Nasdaq: AGMB) raises $208M IPO, funds pipeline to 2029 - Stock Titan
Thu, 06 Aug 2026 20:01:00 GMTAgomab reports €252M cash and expects runway into H1 2029 - Stock Titan
Wed, 05 Aug 2026 00:22:50 GMT36,236,779 Common shares of AgomAb Therapeutics NV are subject to a Lock-Up Agreement Ending on 5-AUG-2026. - marketscreener.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Agomab Therapeutics Nv.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.